©2024 Stanford Medicine
Management of the PDA Trial
Recruiting
Trial ID: NCT03456336
Purpose
Estimate the risks and benefits of active treatment versus expectant management of a
symptomatic patent ductus arteriosus (sPDA) in premature infants.
Official Title
Management of the Patent Ductus Arteriosus in Premature Infants Trial (PDA Trial)
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Postnatal age 48 hours -21 days
- Infant 22 0/7 to 28 6/7 weeks gestation at birth
- sPDA, as defined as:
1. Mild, Moderate, or Severe Clinical Criteria with Small or Moderate size PDA on
echocardiogram
2. Mild or Moderate Clinical Criteria with Large PDA on echocardiogram
Exclusion Criteria:
- Cardiopulmonary compromise
- Known congenital heart disease (besides atrial septal defect or ventricular septal
defect)
- Known pulmonary malformation (e.g. congenital lobar emphysema, congenital pulmonary
adenomatous malformation)
- Any condition which, in the opinion of the investigator, would preclude enrollment
Intervention(s):
other: Active Treatment
other: Expectant Management
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Krisa P. Van Meurs, MD
650-723-5711